Codexis, Inc. (CDXS)

Market Cap	133.58M -41.1%
Revenue (ttm)	70.39M +18.6%
Net Income	-43.97M
EPS	-0.50
Shares Out	90.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,607,520
Open	1.492
Previous Close	1.500
Day's Range	1.420 - 1.555
52-Week Range	0.958 - 3.870
Beta	2.50
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 11, 2026

About CDXS

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The co...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 146
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXS
• Website: https://www.codexis.com

Financial Performance

In 2025, Codexis's revenue was $70.39 million, an increase of 18.61% compared to the previous year's $59.35 million. Losses were -$43.97 million, -32.63% less than in 2024.